Orca Investment Management LLC Invests $3.60 Million in CVS Health Corporation $CVS

Orca Investment Management LLC purchased a new stake in CVS Health Corporation (NYSE:CVS) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 34,836 shares of the pharmacy operator’s stock, valued at approximately $3,604,000. CVS Health comprises about 2.6% of Orca Investment Management LLC’s investment portfolio, making the stock its 10th biggest position.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Beaird Harris Wealth Management LLC raised its stake in CVS Health by 201.0% during the second quarter. Beaird Harris Wealth Management LLC now owns 292 shares of the pharmacy operator’s stock worth $30,000 after purchasing an additional 195 shares during the period. Swiss RE Ltd. purchased a new stake in shares of CVS Health in the 4th quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd increased its holdings in shares of CVS Health by 407.2% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock worth $26,000 after buying an additional 281 shares during the last quarter. Sankala Group LLC acquired a new stake in shares of CVS Health during the 4th quarter worth approximately $28,000. Finally, Mcguire Capital Advisors Inc. purchased a new stake in shares of CVS Health during the 4th quarter valued at approximately $28,000. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Stock Up 2.2%

CVS Health stock opened at $97.09 on Friday. The company has a market capitalization of $124.18 billion, a PE ratio of 25.69, a price-to-earnings-growth ratio of 0.93 and a beta of 0.61. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.66 and a current ratio of 0.87. CVS Health Corporation has a fifty-two week low of $67.42 and a fifty-two week high of $110.68. The firm has a 50 day moving average price of $102.52 and a 200 day moving average price of $88.23.

CVS Health (NYSE:CVS) last released its quarterly earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 EPS for the quarter, topping analysts’ consensus estimates of $1.87 by $0.71. CVS Health had a return on equity of 13.12% and a net margin of 1.18%.The company had revenue of $106.10 billion for the quarter, compared to analysts’ expectations of $100.03 billion. During the same period in the prior year, the firm earned $1.81 earnings per share. The firm’s revenue was up 7.3% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. Research analysts expect that CVS Health Corporation will post 8.02 earnings per share for the current year.

CVS Health Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 23rd were issued a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date was Thursday, July 23rd. CVS Health’s dividend payout ratio (DPR) is 70.37%.

Wall Street Analyst Weigh In

CVS has been the subject of several analyst reports. Morgan Stanley increased their price objective on CVS Health from $106.00 to $111.00 and gave the stock an “overweight” rating in a research report on Thursday, June 4th. TD Cowen lifted their target price on CVS Health from $105.00 to $110.00 and gave the company a “buy” rating in a research report on Monday, May 11th. DA Davidson upped their price target on CVS Health from $80.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Wall Street Zen upgraded CVS Health from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. Finally, Sanford C. Bernstein boosted their price objective on shares of CVS Health from $94.00 to $106.00 and gave the company an “outperform” rating in a report on Tuesday, May 12th. Twenty-two research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $106.75.

Insider Buying and Selling

In other CVS Health news, Director Larry Robbins sold 1,983,538 shares of CVS Health stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $94.45, for a total value of $187,345,164.10. Following the completion of the transaction, the director directly owned 6,213,261 shares of the company’s stock, valued at $586,842,501.45. The trade was a 24.20% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In the last three months, insiders sold 3,372,000 shares of company stock worth $317,473,598. Company insiders own 0.85% of the company’s stock.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.